Listen
SERILIA (Lucilia sericata) - Chronic wounds
Opinions on drugs -
Posted on
May 24 2023
Reason for request
Reassessment
Reassessment.
Key points
Unfavourable opinion for reimbursement in the “debridement of chronic or difficult-to-heal wounds when instrumental/surgical treatment is not desired”.
Clinical Benefit
| Insufficient |
The clinical benefit of SERILIA (Lucilia sericata) larval therapy is insufficient in the MA indication (including the claimed indication “the debridement of chronic necrotic or sloughy wounds, following the failure of debridement after dressing treatment and when instrumental and/or surgical treatment is not possible”) to justify public funding cover. |
Clinical Added Value
| Not applicable |
English version
Contact Us
Évaluation des médicaments
